GoKawiilEating disorder experts report rising severity, link to GLP-1 misuse
Clinical psychologist Cheri Levinson of the University of Louisville says she is seeing more eating disorder patients with more severe symptoms than at any point in her nearly 20-year career, including growing numbers misusing GLP-1 weight-loss drugs. Separately, a study in JAMA Psychiatry led by Ruhai Bai of Children's Hospital of Nanjing Medical University estimated the incidence of anorexia and bulimia across 204 countries and territories from 1990 to 2023, finding rising global health burden from these conditions.
GoKawiil's interpretation of the reporting above, not reported fact.
The clinical observations suggest GLP-1 drugs, widely adopted for weight loss, may be interacting with existing vulnerabilities to eating disorders in ways not yet captured by regulatory or public health guidance. If confirmed by broader data, this could prompt calls for screening or warnings before prescribing these drugs to at-risk populations, though the current evidence is anecdotal rather than from controlled studies.
- A clinical psychologist reports the most severe eating disorder caseload of her 20-year career, with GLP-1 misuse cited as a factor
- A global study estimated anorexia and bulimia incidence across 204 countries from 1990 to 2023 using statistical modeling
- Findings published in JAMA Psychiatry point to a rising disease burden from eating disorders worldwide
Source: technologyreview.com — Jessica Hamzelou, 2026-10-30
Published there as: “Eating disorders are on the rise. GLP-1s could make things worse.”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.